{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibmqymyujtrfyzij6full6b2xgvfalwtcja2sjhfr6rtswh5x5pie",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mndtygdr5c72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigxthgqpnhmtnm7ldfo6ig63j45eabbly5zqp7w5dryfyguaxf444"
    },
    "mimeType": "image/jpeg",
    "size": 801418
  },
  "path": "/news/2026-06-infection-linked-cancer-therapies.html",
  "publishedAt": "2026-06-02T20:00:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers.",
  "title": "Serious infection risks linked to targeted cancer therapies"
}